PDF4PRO ⚡AMP

Modern search engine that looking for books and documents around the web

Example: stock market

Assessment report - Europa

30 Churchill Place Canary Wharf London E14 5EU United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 21 May 2015 EMA/444458/2015 Rev 1 Committee for Medicinal Products for human Use (CHMP) Assessment report Keytruda International non-proprietary name: pembrolizumab Procedure No. EMEA/H/C/003820/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Page 2/160 Table of contents 1. Background information on the procedure.

HIV human immunodeficiency virus . hr Hour(s) IA2 Interim Analysis 2 . IC50 Half-maximal inhibitory concentration . ICH International Conference of Harmonisation . IFN Interferon . IgG Immunoglobulin gamma . IHC immunohistochemistry . IL Interleukin . …

Fullscreen Download
Loading..

Tags:

  Assessment, Report, Human, Assessment report, Immunoglobulin

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Spam in document Broken preview Other abuse

Transcription of Assessment report - Europa

Documents from same domain

products1/traditional herbal medicinal products

www.ema.europa.eu

There is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already

  Product, Medicinal, Traditional, Herbal, Products1 traditional herbal medicinal products, Products1

Q12 Step 2b Technical and regulatory …

www.ema.europa.eu

ICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36

  Product, Management, Lifecycle, Product lifecycle management

Guideline on good pharmacovigilance practices …

www.ema.europa.eu

9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)

  Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance

Guideline on good pharmacovigilance practices (GVP)

www.ema.europa.eu

Guideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25

  Good, Practices

Guideline on good pharmacovigilance practices …

www.ema.europa.eu

Guideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28

  Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance

Guideline for good clinical practice E6(R2)

www.ema.europa.eu

Guideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification

  Good, Practices, Clinical, Good clinical practice

Guideline for good clinical practice E6(R2)

www.ema.europa.eu

Guideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November

  Guidelines, Good, Practices, Clinical, Good clinical practice e6

Guideline on good pharmacovigilance practices …

www.ema.europa.eu

harmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product

  Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance

European Medicines Agency

www.ema.europa.eu

© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline

  Guidelines, European, Agency, Medicine, Harmonised, European medicines agency, Ich harmonised

Q7 Q&A - good manufacturing practice for active ...

www.ema.europa.eu

ICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37

  Good, Practices, Pharmaceutical, Manufacturing, Active, Ingredients, Good manufacturing practice for active, Good manufacturing practice for active pharmaceutical ingredients

Related documents

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

www.ema.europa.eu

humanized immunoglobulin G1 [IgG1], produced in Chinese Hamster Ovary cells by recombinant ... recommended dose of bendamustine is 90 mg/m. 2 /day on Day 1 and Day 2 of each cycle and the . 3 . ... than 1.5 × upper limit of normal [ULN]) should be avoided.

  Product, Summary, Normal, Characteristics, Immunoglobulin, Summary of product characteristics

Update on the use of immunoglobulin in human disease: A ...

www.aaaai.org

based guideline on immunoglobulin therapy, last published in 2006. Given the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indications and administration is warranted. (J Allergy Clin Immunol 2017;139:S1-46.) Key words: Immune globulin, immunoglobulin, IVIG, SCIG, IGIV,

  Human, Immunoglobulin, Human immunoglobulin

Primary Biliary Cholangitis: 2018 Practice Guidance from ...

www.aasld.org

are symptom free and liver tests are normal.(40) Long-term follow-up of 229 AMA-positive individuals for up to 7 years found that the 5-year incidence of PBC was 16%. In a smaller study, the median time from the first positive AMA test to persistently abnormal liver tests was 6 years, with a range between 1 and 19 years;

  Practices, Guidance, Primary, 2018, Normal, Biliary, Cholangitis, Primary biliary cholangitis, 2018 practice guidance

100 CASES - M. I. Alhefzi

www.alhefzi.com

On bimanual examination the uterus is non-tender and of normal size, axial and mobile. There are no adnexal masses. Normal range Haemoglobin 12.7g/dL 11.7–15.7g/dL White cell count 4.5 910 /L 3.5–11 109/L Platelets 401 109/L 150–440 109/L INVESTIGATIONS Figure 1.1 Questions • What is the diagnosis and differential diagnosis?

  Normal

Related search queries

SUMMARY OF PRODUCT CHARACTERISTICS, Immunoglobulin, Normal, Human, Human immunoglobulin, Primary Biliary Cholangitis: 2018 Practice Guidance